Cargando…

Efficient Downregulation of Alk4 in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular Dystrophy

Downregulation of genes involved in the secondary pathology of Duchenne muscular dystrophy, for example, inflammation, fibrosis, and adiposis, is an interesting approach to ameliorate degeneration of muscle and replacement by fibrotic and adiposis tissue. Small interfering RNAs (siRNAs) are able to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engelbeen, Sarah, Pasteuning-Vuhman, Svetlana, Boertje-van der Meulen, Joke, Parmar, Rubina, Charisse, Klaus, Sepp-Lorenzino, Laura, Manoharan, Muthiah, Aartsma-Rus, Annemieke, van Putten, Maaike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2023
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940804/ https://www.ncbi.nlm.nih.gov/pubmed/36269327 http://dx.doi.org/10.1089/nat.2022.0021

Ejemplares similares

Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy
por: van Putten, Maaike, et al.
Publicado: (2019)

Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the mdx Mouse Model for Duchenne Muscular Dystrophy
por: Engelbeen, Sarah, et al.
Publicado: (2021)

A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2019)

New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration
por: Pasteuning-Vuhman, Svitlana, et al.
Publicado: (2017)

Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
por: Jirka, Silvana M G, et al.
Publicado: (2015)

Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
por: Pasteuning-Vuhman, S., et al.
Publicado: (2018)

Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F
por: Pasteuning-Vuhman, S., et al.
Publicado: (2017)

Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F
por: Verhaart, Ingrid E. C., et al.
Publicado: (2019)

The use of genetically humanized animal models for personalized medicine approaches
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2019)

Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy
por: Kogelman, Bauke, et al.
Publicado: (2018)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Centyrin ligands for extrahepatic delivery of siRNA
por: Klein, Donna, et al.
Publicado: (2021)

The importance of genetic diagnosis for Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2016)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
por: Veltrop, Marcel, et al.
Publicado: (2018)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model
por: Marchal, Gerard A., et al.
Publicado: (2021)

Moving neuromuscular disorders research forward: from novel models to clinical studies
por: van Putten, Maaike, et al.
Publicado: (2020)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
por: van Putten, Maaike, et al.
Publicado: (2014)

Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy
por: Kinnett, Kathi, et al.
Publicado: (2015)

Nonclinical Exon Skipping Studies with 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn−/− Mice Inspired by Clinical Trial Results
por: van Putten, Maaike, et al.
Publicado: (2019)

Generation of Embryonic Stem Cells and Mice for Duchenne Research
por: Veltrop, Marcel, et al.
Publicado: (2013)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2007)

The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)

Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor
por: Kemaladewi, Dwi U, et al.
Publicado: (2014)

Spatial transcriptomics reveal markers of histopathological changes in Duchenne muscular dystrophy mouse models
por: Heezen, L.G.M., et al.
Publicado: (2023)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
por: van Vliet, Laura, et al.
Publicado: (2008)

CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies
por: Chey, Yu C. J., et al.
Publicado: (2022)

Case Report: The Genetic Diagnosis of Duchenne Muscular Dystrophy in the Middle East
por: Alghamdi, Fouad, et al.
Publicado: (2021)

Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
por: Doorenweerd, Nathalie, et al.
Publicado: (2017)

Author Correction: Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
por: Doorenweerd, Nathalie, et al.
Publicado: (2018)

siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2
por: Elkayam, Elad, et al.
Publicado: (2017)

siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2
por: Elkayam, Elad, et al.
Publicado: (2017)

Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models
por: Tsonaka, Roula, et al.
Publicado: (2020)

Sensitive and reliable evaluation of single-cut sgRNAs to restore dystrophin by a GFP-reporter assay
por: Lyu, Pin, et al.
Publicado: (2020)

Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
por: Kemaladewi, Dwi U, et al.
Publicado: (2011)

The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23
por: Aartsma-Rus, Annemieke
Publicado: (2022)

Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
por: Johansson, Camilla, et al.
Publicado: (2023)

From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization
por: Schlegel, Mark K, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_abpv6439sa3cac2jjavbufi8m0